{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088970","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.283323+00:00","generated_at":"2026-05-18T23:49:26.453876+00:00","sec_items":["4.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Aptevo Therapeutics appoints Baker Tilly as new auditor after Moss Adams merger","bullets":["Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned and Baker Tilly appointed for FY2025.","No disagreements or reportable events with Moss Adams during 2024/2023 and subsequent interim period.","Prior audit reports from Moss Adams included a going concern uncertainty explanatory paragraph."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088970","json":"https://secwatch.observer/filing/0000950170-25-088970.json","markdown":"https://secwatch.observer/filing/0000950170-25-088970.md","text":"https://secwatch.observer/filing/0000950170-25-088970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088970/0000950170-25-088970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088970/apvo-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:49:26.453876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"439375d2ad0e4f7a1f07438931912c895ca85c8f","claim":"Aptevo Therapeutics Inc. engaged Baker Tilly US, LLP as its auditor.","evidence_excerpt":"the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the year ending December 31, 2025","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088970/0000950170-25-088970-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Baker Tilly US, LLP"}],"fact_type":"auditor_change"},{"claim_id":"dde530af3371051a4580a2ae690a7bf9ef76812e","claim":"Moss Adams LLP resigned as auditor of Aptevo Therapeutics Inc..","evidence_excerpt":"On June 23, 2025, Aptevo Therapeutics Inc., (the \"Company\") was notified that Moss Adams LLP (\"Moss Adams\"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025088970/0000950170-25-088970-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"resignation"},{"label":"Auditor","value":"Moss Adams LLP"},{"label":"Successor","value":"Baker Tilly US, LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}